Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Amgen Inc. (“Amgen” or the “Company”) (Nasdaq: AMGN) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at brian@lundinlawpc.com.
On May 22, 2017, Amgen revealed that its osteoporosis medicine, Evenity, raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by the Company, a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, than those who took an older approved medicine.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523006305/en/
Contacts:
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
